RxDoctor Payments Data

Mandhir Jamwal, MD

Family Medicine · West Branch, MINPI 1932302346

Payments from drug & device makers

$3,869in general payments, 2019–2025

Across 218 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$650
  • Lilly USA, LLC$548
  • AstraZeneca$375
  • Novartis$243
  • Novo Nordisk$233
  • Boehringer Ingelheim$223
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$3,84699%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,869 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$56,601
Medicare patients
219
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$63,067
TrulicityDulaglutide51$54,430
JardianceEmpagliflozin28$37,106
EliquisApixaban33$23,632
FarxigaDapagliflozin Propanediol15$19,914
TradjentaLinagliptin28$17,447
XareltoRivaroxaban22$15,923
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,331
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,305
Restasis MultidoseCyclosporine13$7,893
MyrbetriqMirabegron11$5,270
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,633
Albuterol Sulfate HfaAlbuterol Sulfate85$3,334
SymbicortBudesonide/Formoterol Fumarate12$2,664
Atorvastatin Calcium173$1,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$548$117,497102 claims
Boehringer IngelheimJardiance, Tradjenta$223$54,55356 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$375$37,90944 claims
PfizerEliquis$163$23,63233 claims
Johnson & JohnsonXarelto$136$15,92322 claims
GSKTrelegy Ellipta$12$9,30513 claims
AbbVieRestasis Multidose$650$7,89313 claims
Astellas Pharma US IncMyrbetriq$174$5,27011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in West Branch

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →